Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | NMBR | P28336 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071662 | 0.76 | MTNR1A (0.42) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL2071508 | 0.76 | HTR2A (0.43) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL3160102 | 0.75 | MTNR1A (0.40) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL5199276 | 0.73 | HTR2A (0.43) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL5230865 | 0.70 | HTR2A (0.41) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL5230871 | 0.67 | HTR2A (0.45) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL5202211 | 0.66 | MTNR1A (0.52) | MTNR1AMTNR1BHTR2ASCN5ASCN2A | |
| SCHEMBL13451646 | 0.64 | SLC6A2 (0.39) | HTR2ANMBR | |
| SCHEMBL2073706 | 0.62 | HDAC3 (0.44) | MTNR1AMTNR1BHTR2A | |
| SCHEMBL1714014 | 0.60 | MTNR1A (0.46) | MTNR1AMTNR1BHTR2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | MTNR1A 40/4885MTNR1B 56/4885HTR2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.